Shares of Codexis CDXS fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 500.00% year over year to ($0.06), which beat the estimate of ($0.12).
Revenue of $21,034,000 higher by 12.78% year over year, which beat the estimate of $20,880,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $82,000,000 and $85,000,000.
Details Of The Call
Date: Feb 25, 2021
Time: 04:30 PM
ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/cdx/mediaframe/43591/indexl.html
Technicals
52-week high: $29.56
Company's 52-week low was at $8.43
Price action over last quarter: Up 46.48%
Company Profile
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases etc. The company operates in two business segment namely Performance Enzymes and Novel Biotherapeutics.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
